{
    "ticker": "CRDF",
    "name": "Cardiff Oncology, Inc.",
    "description": "Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapeutics for cancer treatment. Founded in 2007 and based in San Diego, California, the company is dedicated to advancing the field of oncology through its proprietary drug platform and novel treatment approaches. Cardiff's lead product candidate, onvansertib, is designed to inhibit the protein kinase involved in cancer cell division and has shown promise in various clinical trials, particularly in combination with established therapies for patients with solid tumors and hematological malignancies. The company is committed to improving outcomes for cancer patients by pursuing targeted therapies that aim to enhance efficacy while minimizing toxicity. With a dedicated team of scientists and clinical researchers, Cardiff Oncology is actively involved in multiple clinical trials to evaluate the safety and efficacy of its drug candidates. Their research focuses on leveraging biomarker-driven approaches to optimize patient selection and treatment regimens. As a forward-thinking company, Cardiff is well-positioned to contribute to the evolving landscape of cancer therapeutics, with the ultimate goal of providing better treatment options for patients battling this devastating disease.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2007",
    "website": "https://www.cardiffoncology.com",
    "ceo": "Douglas J. M. B. S. M. H. A. J. C. R. H. M. C. C. R. E.",
    "social_media": {
        "twitter": "https://twitter.com/CardiffOncology",
        "linkedin": "https://www.linkedin.com/company/cardiff-oncology/"
    },
    "investor_relations": "https://ir.cardiffoncology.com",
    "key_executives": [
        {
            "name": "Douglas J. M. B. S. M. H. A. J. C. R. H. M. C. C. R. E.",
            "position": "CEO"
        },
        {
            "name": "Michael J. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "Onvansertib"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cardiff Oncology, Inc. | Innovative Cancer Therapeutics",
        "meta_description": "Explore Cardiff Oncology, Inc., a clinical-stage biotechnology company focused on developing targeted therapeutics for cancer treatment. Discover our lead product candidate and commitment to improving patient outcomes.",
        "keywords": [
            "Cardiff Oncology",
            "Cancer Treatment",
            "Oncology",
            "Biotechnology",
            "Onvansertib"
        ]
    },
    "faq": [
        {
            "question": "What is Cardiff Oncology known for?",
            "answer": "Cardiff Oncology is known for developing innovative therapeutics for cancer treatment, particularly its lead product candidate, onvansertib."
        },
        {
            "question": "Who is the CEO of Cardiff Oncology?",
            "answer": "Douglas J. M. B. S. M. H. A. J. C. R. H. M. C. C. R. E. is the CEO of Cardiff Oncology, Inc."
        },
        {
            "question": "Where is Cardiff Oncology headquartered?",
            "answer": "Cardiff Oncology is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Cardiff Oncology's main product?",
            "answer": "Cardiff Oncology's main product candidate is onvansertib, which is in clinical trials for cancer treatment."
        },
        {
            "question": "When was Cardiff Oncology founded?",
            "answer": "Cardiff Oncology was founded in 2007."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "NVS",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "MRNA",
        "BMY"
    ]
}